Akinesia is the inability to perform a clinically perceivable movement. It can show up as a total freeze, a long delay before a movement starts, or a sudden stop mid-action. The term comes from the second half of the 19th century and literally means “without movement.” While most closely associated with Parkinson’s disease, akinesia can also result from certain medications, other neurological conditions, and severe thyroid problems.
Akinesia, Bradykinesia, and Hypokinesia
These three terms are often used interchangeably, even in clinical settings, but they describe different problems. Akinesia means no movement or a failure to initiate movement. Bradykinesia means reduced speed of movement. Hypokinesia means reduced size or amplitude of movement. A person with bradykinesia can still move, just slowly. A person with hypokinesia moves at a more normal speed but with smaller motions, like handwriting that gradually shrinks. A person with akinesia may be temporarily unable to move at all.
In practice, these three problems frequently overlap, especially in Parkinson’s disease. A doctor might use “bradykinesia” as a blanket term covering all three. But the distinction matters because each reflects a slightly different disruption in how the brain plans and executes movement.
What Happens in the Brain
Voluntary movement depends on a group of deep brain structures called the basal ganglia, which act as a kind of relay system, fine-tuning the signals your brain sends to your muscles. Dopamine, a chemical messenger, is essential for this relay to work properly. In Parkinson’s disease, dopamine-producing cells in a specific part of the brainstem progressively die off. As dopamine levels in the basal ganglia drop, the circuits that initiate and sustain movement start to malfunction.
The basal ganglia use two main pathways to regulate movement, sometimes called the “go” pathway and the “stop” pathway. Each relies on a different type of dopamine receptor. When dopamine is depleted, both pathways are disrupted, but in different ways. One pathway loses its normal firing rate, making it harder to generate enough neural activity to start a movement. The other pathway loses its timing coordination, causing neurons to fire in abnormally synchronized bursts that essentially lock up the motor system. The combination of these two disruptions produces the characteristic freeze of akinesia.
What Akinesia Feels Like
People with akinesia often describe feeling “frozen” or “stuck.” The muscles aren’t paralyzed in the traditional sense. The strength is still there, but the brain fails to build up adequate power to get a movement going. This can happen in several ways:
- Freezing of gait: Your feet feel glued to the floor, especially when turning, passing through doorways, or navigating tight spaces.
- Delayed movement initiation: You intend to reach for a cup or stand up from a chair, but nothing happens for several seconds.
- Mid-action freezing: A movement starts normally but suddenly stops partway through.
- Festination: A tendency to involuntarily speed up repetitive movements or speech, almost as if the body is trying to compensate for the difficulty starting.
Akinesia in Parkinson’s disease rarely appears alone. It typically comes alongside a resting tremor, muscle rigidity (sometimes with a ratcheting “cogwheel” quality), and postural instability that increases the risk of falls. Reduced facial expression, sometimes called “masking,” is another common feature, where the face appears blank even when the person is experiencing strong emotions.
In progressive supranuclear palsy, a rarer condition, akinesia affects the body’s trunk and core more than the limbs. Early signs often include unexplained falls, general motor slowing, and difficulty moving the eyes vertically.
Common Causes
Parkinson’s disease is by far the most common cause, particularly in its later stages as dopamine depletion becomes more severe. But akinesia can also be triggered by medications that block dopamine. Typical antipsychotics like haloperidol and chlorpromazine are the most frequent culprits, though newer “atypical” antipsychotics can cause it too. Drugs used for digestive problems, such as metoclopramide, certain calcium channel blockers, some anti-seizure medications, and lithium have all been linked to drug-induced parkinsonism that can include akinesia.
Severe hypothyroidism is another recognized cause. When thyroid hormone levels drop very low, motor function can deteriorate to the point of akinesia. This form is potentially reversible with thyroid hormone replacement, unlike the progressive akinesia of Parkinson’s disease.
How Akinesia Is Assessed
There is no single blood test or brain scan that diagnoses akinesia. Neurologists primarily rely on clinical observation, watching how you move, how quickly you can start and stop movements, and whether freezing occurs. The standard tool is a structured motor exam called the MDS-UPDRS Part III, which scores specific tasks like finger tapping, hand rotation, and walking.
A simpler tool called the BRAIN tap test can be done on a regular computer keyboard. You alternate tapping two keys as fast as possible, and the software measures how many taps you produce, how long each key press lasts (the “akinesia time”), and whether your tapping rhythm and speed decline over the course of the test. That decline, known as the sequence effect, is a hallmark of akinesia: movements don’t just start slow, they progressively deteriorate with repetition.
Medication Treatment
The primary treatment for akinesia caused by Parkinson’s disease is levodopa, a precursor that the brain converts into dopamine. It is most effective at controlling slowed and frozen movement. Treatment typically starts at a low dose and increases gradually, with a target range of 300 to 1,200 mg per day split across multiple doses throughout the day. The dose is raised by about 100 mg every three to four days until symptoms improve.
Levodopa works well in early and moderate Parkinson’s, but its effectiveness can fluctuate over time. Many people develop “on-off” periods where the medication works for part of the day and then wears off, causing akinesia to return before the next dose kicks in. Adjusting dose timing, adding other medications that extend levodopa’s effect, or switching to extended-release formulations can help manage these fluctuations.
When akinesia is caused by a medication, the most effective approach is reducing the dose or switching to a drug less likely to block dopamine. This type of akinesia often improves within weeks to months after the offending drug is stopped, though in some cases it can take longer.
Deep Brain Stimulation
For people with moderate to advanced Parkinson’s disease who no longer get reliable relief from medication, deep brain stimulation (DBS) is a surgical option. Thin electrodes are implanted in the subthalamic nucleus, a small structure deep in the brain, and connected to a battery-powered device similar to a pacemaker. The device delivers continuous electrical pulses that help normalize the disrupted basal ganglia circuits.
Results from the INTREPID trial, which followed patients for five years, showed that motor function improved by 51% in the first year after surgery (measured without medication, with stimulation on). By year five, improvement had settled to about 36%, still a substantial benefit. Bradykinesia and akinesia specifically improved by 42% in the first year, declining to 25% improvement by year five. Tremor and rigidity tended to hold their improvement better over time, while slowness and freezing gradually worsened as the underlying disease progressed. DBS does not stop disease progression, but it can provide years of meaningful motor improvement.
Cueing and Physical Therapy
One of the more practical strategies for managing akinesia, particularly freezing of gait, involves external cues. These are rhythmic signals that essentially give the brain an external trigger to step when internal movement signals fail. The concept is straightforward: if you can’t internally generate the command to take a step, an outside rhythm can substitute.
Cueing comes in three forms. Auditory cues are the most popular, chosen by about two-thirds of patients in a large home-based trial called RESCUE. These can be as simple as a metronome beat through earphones or music with a steady tempo. Somatosensory cues use small vibrations worn on the wrist, and about a third of patients preferred this option for its discreteness. Visual cues use rhythmic light flashes. In the trial, patients matched their heel strikes to the cue rhythm and practiced walking through the exact situations that trigger freezing: doorways, tight turns, changes in surface, and walking while talking or carrying something.
Cueing training improved step length, walking speed, and balance, and helped reduce freezing episodes. The approach is low-cost and can be done at home with nothing more than a metronome app and earphones. For many people with Parkinson’s-related akinesia, this kind of targeted physical therapy becomes a daily management tool alongside medication.